Prostate Cancer
Conditions
Keywords
Bipolar Androgen Therapy, Testosterone, Enzalutamide, Abiraterone, Androgen Ablative Therapies
Brief summary
Single-arm, single site, open label study of the effects of parenteral testosterone followed by enzalutamide, abiraterone or castration-only therapy in men with metastatic CRPC who previously progressed on one of these forms of therapy. The study will enroll four cohorts of patients: men with metastatic CRPC who have progressed on enzalutamide (Cohort A; n=30); men with metastatic CRPC who have progressed on abiraterone acetate (Cohort B; n=30); men with metastatic CRPC who have progressed on first line castration-only therapy (Cohort C; n=30); men with metastatic CRPC with inactivating somatic or germline mutations in ≥2 of the genes TP53, PTEN, or RB1 (Cohort D; n=20).
Detailed description
The trial will enroll up to 110 patients, 30 for each Cohorts A-C and 20 for Cohort D. Eligible patients will continue on androgen ablative therapy with LHRH agonist (i.e. Zoladex, Trelstar, Eligard or Lupron) if not surgically castrated to suppress endogenous testosterone production. Patients will also receive intramuscular injection with either testosterone cypionate or testosterone enanthate at a dose of 400 mg every 28 days. This dosing scheme was designed to produce rapidly fluctuating serum testosterone levels from the supraphysiologic to the near-castrate range (i.e. Bipolar Androgen Therapy \[BAT\]). Assessments for response to testosterone will be made approximately every 3 months. Upon displaying evidence of progression, patients will then go on to receive either abiraterone (Cohort B) or enzalutamide (Cohort A), whichever agent they had previously progressed on prior to study enrollment. Patients in Cohort C will remain on LHRH agonist therapy and receive no additional androgen ablative hormonal therapy while those in the mutation-positive Cohort D will receive enzalutamide regardless of prior therapy.
Interventions
DRUGTestosterone cypionate
DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. DEPO-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate and will be administered at 400mg IM every 28 days.
DRUGTestosterone Enanthate
Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative. Will be administered at 400mg IM every 28 days.
DRUGAbiraterone acetate
Abiraterone is an inhibitor of CYP17 (17α-hydroxylase/C17,20-lyase). Each ZYTIGA tablet contains 250 mg of abiraterone acetate.
DRUGEnzalutamide
XTANDI is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides.
Sponsors
National Cancer Institute (NCI)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Performance status ≤2 * Age ≥18 years * Histologically-confirmed adenocarcinoma of the prostate * Progressing on continuous androgen ablative therapy (either surgical castration or LHRH agonist). * Documented castrate level of serum testosterone (\<50 ng/dl). * For Cohorts A and B, patients must have progressed on prior treatment with enzalutamide or abiraterone acetate + prednisone (by PSA criteria or radiographically). * For castration-only Cohort C, patients must have developed castrate resistant prostate cancer after progressing on first line hormone therapy with either surgical castration or LHRH agonist or LHRH agonist plus an anti-androgen. * For Cohort D patients must have inactivating somatic or germline mutations in ≥2 of the genes TP53, PTEN, RB1 * Patients progressing on LHRH agonist plus an anti-androgen as first line therapy must be off anti-androgen for 4 weeks prior to first treatment with testosterone. * Patients with rising PSA on two successive measurements at least two weeks apart. * For Cohort A (enzalutamide) and Cohort B (abiraterone acetate): * Prior treatment with up to 2 additional second line hormone therapies, including ketoconazole is allowed. * Patients who have progressed on both enzalutamide and abiraterone acetate are eligible and post-BAT will be retreated with the last second line agent they had received (e.g. patient receiving abiraterone then enzalutamide would receive retreatment with enzalutamide post-BAT). * Patients must be withdrawn from enzalutamide or abiraterone acetate for ≥ 4 weeks and have documented PSA increase after the withdrawal period. * Patients receiving prednisone in conjunction with abiraterone acetate must be weaned off prednisone prior to starting BAT. * For Cohort C (castration-only): * Patients must continue on castrating therapy throughout BAT treatment. * No prior second line hormone treatment with flutamide, bicalutamide, nilutamide, enzalutamide, abiraterone, ketoconazole, ARN-509 or other investigational androgen ablative therapies is permitted for Cohort C. * For Cohort D (mutation cohort): * Patients must continue on castrating therapy throughout BAT treatment. * Treatment with first-generation hormonal therapy (i.e. flutamide, bicalutamide, nilutamide), is allowed * Patient must have received at least one and not more than two second generation hormone therapies (i.e. enzalutamide, abiraterone, apalutamide). * For Cohorts A-D, prior docetaxel for hormone-sensitive prostate cancer is permitted if ≤ 6 doses were given in conjunction with first-line androgen deprivation therapy and \>12 months since last dose of docetaxel * For Cohort D, one line of prior chemotherapy with docetaxel or cabazitaxel for metastatic castrate resistant prostate cancer is allowed * Acceptable liver function: * Bilirubin \< 2.5 times institutional upper limit of normal (ULN) * AST (SGOT) and ALT (SGPT) \< 2.5 times ULN * Acceptable renal function: \-- Serum creatinine \< 2.5 times ULN, OR * Acceptable hematologic status: * Absolute neutrophil count (ANC) ≥ 1500 cells/mm3 (1.5 ×109/L) * Platelet count ≥ 100,000 platelet/mm3 (100 ×109/L) * Hemoglobin ≥ 9 g/dL. * At least 4 weeks since prior surgery with full recovery (no persistent toxicity ≥ Grade 1). * Ability to understand and willingness to sign a written informed consent document.
Exclusion criteria
* Pain due to metastatic prostate cancer requiring opioid analgesics. * \>5 sites of visceral disease in lung or liver (nonspecific lung nodules ≤1 cm in diameter are permitted). * Prior treatment with docetaxel or cabazitaxel for metastatic castration-resistant prostate cancer is prohibited. * Prior treatment with one line of chemotherapy for metastatic castration-resistant prostate cancer is allowed for Cohort D * Requires urinary catheterization for voiding due to obstruction secondary to prostatic enlargement thought to be due to prostate cancer or benign prostatic hyperplasia * Evidence of disease in sites or extent that, in the opinion of the investigator, would put the patient at risk from therapy with testosterone (e.g. femoral metastases with concern over fracture risk, spinal metastases with concern over spinal cord compression, lymph node disease with concern for ureteral obstruction). * Evidence of serious and/or unstable pre-existing medical, psychiatric or other condition (including laboratory abnormalities) that could interfere with patient safety or provision of informed consent to participate in this study. * Active uncontrolled infection, including known history of AIDS or hepatitis B or C. * Any psychological, familial, sociological, or geographical condition that could potentially interfere with compliance with the study protocol and follow-up schedule. * Prior history of a thromboembolic event within the last two years and not currently on systemic anticoagulation. * Hematocrit \>50%, untreated severe obstructive sleep apnea, uncontrolled or poorly controlled heart failure \[per Endocrine Society Clinical Practice Guidelines (67)\].
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prostate Specific Antigen (PSA) Response to Bipolar Androgen Therapy (BAT) | up to 18 months | Number of participants with ≥50% PSA reduction from pre-BAT baseline level |
| PSA Response to Enzalutamide or Abiraterone Acetate Post Bipolar Androgen Therapy | up to 24 months | Number of participants with ≥50% PSA reduction after enzalutamide or abiraterone acetate post-BAT from baseline |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease Response as Defined by RECIST 1.1 (Soft Tissue Lesions) and PCWG2 Criteria (Bone Lesions) | up to 18 months | Number of participants with complete or partial response post-BAT as defined by RECIST 1.1 (for soft tissue lesions) and PCWG2 criteria (for bone disease), or return to castration-only post-BAT. |
| Initiation of Docetaxel Chemotherapy | up to 18 months | Time to initiation of docetaxel chemotherapy |
| Quality of Life (QoL) as Assessed by FACIT-F Score | up to 18 months | Functional Assessment of Chronic Illness Therapy, Fatigue Subscale (FACIT-F) assesses Fatigue with a total score range of 0-52, with a higher score reflecting better QoL. |
| Safety and Tolerability as Assessed by Number of Participants With Adverse Events | 18 months | Number of participants who experience adverse events, as defined by NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.0. |
| PSA Progression on Enzalutamide or Abiraterone Acetate or Castrate Levels Post-BAT | up to 18 months | Time to PSA progression on enzalutamide or abiraterone acetate or return to castrate levels of testosterone post-BAT, defined as the time from the date of re-initiation of enzalutamide or abiraterone acetate or castration-only therapy to the date of the PSA measurement when it shows an increase by ≥25% above the nadir value that occurred following re-initiation of enzalutamide or abiraterone acetate or castration-only therapy and confirmed by a repeat PSA 4 weeks later (PCWG2). |
| Quality of Life (QoL) as Assessed by BPI | up to 18 months | Brief Pain Inventory (BPI) assesses the severity of pain and its impact on functioning with scales ranging from 0-10, with a higher score indicating a higher level of pain. |
| Quality of Life (QoL) as Assessed by IIEF | up to 18 months | International Index of Erectile Function (IIEF-5) is a diagnostic tool for erectile dysfunction, with a total score range of 5-25, with the lowest score indicating a higher degree of dysfunction. |
| Quality of Life (QoL) as Assessed by PANAS | up to 18 months | Positive and Negative Affect Schedule (PANAS) is a self-report measure that is made up of two mood scales, one measuring positive affect and the other measuring negative affect, with a total score range from 10-50 with a higher score on the positive scale indicating greater levels of positive affect and a lower score on the negative scale indicating less of a negative affect. |
| Quality of Life (QoL) as Assessed by RANDSF-36 | up to 18 months | RAND 36-Item Short Form (RANDSF-36) assesses physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, general health perceptions, and perceived change in health with a total score range of 0-100. The total score from all of the questions answered is divided by the total number of the questions answered yielding a global score from 0-100, with a higher score reflecting a better QoL. |
| PSA Progression on BAT (Bipolar Androgen Therapy ) | up to 18 months | Time to PSA progression on BAT. Time to PSA progression on BAT is defined as the time from the date of initial dose of Testosterone to the date of the PSA measurement when it shows an ≥25% increase above the nadir value and confirmed by a repeat PSA 4 weeks later (PCWG2 criteria) during the treatment with BAT. |
Countries
United States
Participant flow
Pre-assignment details
16 patients failed screen.
Participants by arm
| Arm | Count |
|---|---|
| Cohort A:Post-enzalutamide Men with castration-resistant prostate cancer who have progressed on enzalutamide will be enrolled to this cohort. These patients will then receive intramuscular injections with testosterone cypionate 400 mg every 28 days or testosterone enanthate 400 mg every 28 days. Upon progression on testosterone cypionate or enanthate, men will be retreated with enzalutamide 160 mg by mouth daily.
Testosterone cypionate: DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. DEPO-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate and will be administered at 400mg IM every 28 days.
Testosterone Enanthate: Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative. Will be administered at 400mg IM every 28 days.
Enzalutamide: XTANDI is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides. | 30 |
| Cohort B: Post-abiraterone Men with castration-resistant prostate cancer who have progressed on abiraterone will be enrolled to this cohort. These patients will then receive intramuscular injections with testosterone cypionate 400 mg every 28 days or testosterone enanthate 400 mg every 28 days. Upon progression on testosterone cypionate or enanthate, men will be retreated with abiraterone 1000 mg by mouth daily.
Testosterone cypionate: DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. DEPO-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate and will be administered at 400mg IM every 28 days.
Testosterone Enanthate: Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative. Will be administered at 400mg IM every 28 days.
Abiraterone acetate: Abiraterone is an inhibitor of CYP17 (17α-hydroxylase/C17,20-lyase). Each ZYTIGA tablet contains 250 mg of abiraterone acetate. | 29 |
| Cohort C: Castration Only Men with metastatic prostate cancer who have only received first line hormone therapy with LHRH agonist alone or LHRH agonist plus an anti-androgen. Patients who have developed castrate resistance to first line therapy and have then received second line hormone therapy of any kind (including flutamide, bicalutamide, nilutamide, ketoconazole, abiraterone, enzalutamide, ARN-509 and investigational anti-androgens) are not eligible for enrollment in this cohort.
Testosterone cypionate: DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. DEPO-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate and will be administered at 400mg IM every 28 days.
Testosterone Enanthate: Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative. Will be administered at 400mg IM every 28 days. | 29 |
| Cohort D: Mutation Men with metastatic prostate cancer who have castrate resistant prostate cancer with inactivating somatic or germline mutations in the genes TP53, RB1 or PTEN identified using clinical grade sequencing of tumor tissue performed by qualified laboratory. Patients must have mutations in ≥2 of these genes to be eligible. Eligible patients must have progressed on first line hormone therapy with LHRH agonist alone and must have received at least one but not more than two second generation androgen ablative therapy (i.e. Abiraterone, Enzalutamide or Apalutamide).
Testosterone cypionate: DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. DEPO-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate and will be administered at 400mg IM every 28 days.
Testosterone Enanthate: Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative. Will be administered at 400mg IM every 28 days. | 8 |
| Total | 96 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Overall Study | Adverse Event | 1 | 2 | 2 | 0 |
| Overall Study | Death | 1 | 0 | 1 | 0 |
| Overall Study | Physician Decision | 5 | 0 | 1 | 1 |
| Overall Study | Progressive Disease | 20 | 21 | 23 | 6 |
| Overall Study | Withdrawal by Subject | 3 | 6 | 2 | 1 |
Baseline characteristics
| Characteristic | Total | Cohort B: Post-abiraterone | Cohort A:Post-enzalutamide | Cohort D: Mutation | Cohort C: Castration Only |
|---|---|---|---|---|---|
| Age, Continuous | 72 Years | 71 Years | 74 Years | 73 Years | 69 Years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 2 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 81 Participants | 26 Participants | 24 Participants | 7 Participants | 24 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 13 Participants | 3 Participants | 6 Participants | 0 Participants | 4 Participants |
| Race/Ethnicity, Customized Non-white | 13 Participants | 3 Participants | 3 Participants | 1 Participants | 6 Participants |
| Race/Ethnicity, Customized White | 83 Participants | 26 Participants | 27 Participants | 7 Participants | 23 Participants |
| Region of Enrollment United States | 96 Participants | 29 Participants | 30 Participants | 8 Participants | 29 Participants |
| Sex: Female, Male Female | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Sex: Female, Male Male | 96 Participants | 29 Participants | 30 Participants | 8 Participants | 29 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 1 / 30 | 0 / 29 | 1 / 29 | 0 / 8 |
| other Total, other adverse events | 30 / 30 | 29 / 29 | 29 / 29 | 8 / 8 |
| serious Total, serious adverse events | 3 / 30 | 4 / 29 | 5 / 29 | 1 / 8 |
Outcome results
Primary
Prostate Specific Antigen (PSA) Response to Bipolar Androgen Therapy (BAT)
Number of participants with ≥50% PSA reduction from pre-BAT baseline level
Time frame: up to 18 months
Population: Only 7/8 patients were evaluable from Cohort D.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort A:Post-enzalutamide | Prostate Specific Antigen (PSA) Response to Bipolar Androgen Therapy (BAT) | 9 Participants |
| Cohort B: Post-abiraterone | Prostate Specific Antigen (PSA) Response to Bipolar Androgen Therapy (BAT) | 5 Participants |
| Cohort C: Castration Only | Prostate Specific Antigen (PSA) Response to Bipolar Androgen Therapy (BAT) | 4 Participants |
| Cohort D: Mutation | Prostate Specific Antigen (PSA) Response to Bipolar Androgen Therapy (BAT) | 2 Participants |
Primary
PSA Response to Enzalutamide or Abiraterone Acetate Post Bipolar Androgen Therapy
Number of participants with ≥50% PSA reduction after enzalutamide or abiraterone acetate post-BAT from baseline
Time frame: up to 24 months
Population: This outcome measure only applies to cohort A,B, and D. Only 22/30 (Cohort A), 19/29 (Cohort B) and 7/8 (Cohort D) patients had evaluable data.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort A:Post-enzalutamide | PSA Response to Enzalutamide or Abiraterone Acetate Post Bipolar Androgen Therapy | 15 Participants |
| Cohort B: Post-abiraterone | PSA Response to Enzalutamide or Abiraterone Acetate Post Bipolar Androgen Therapy | 3 Participants |
| Cohort D: Mutation | PSA Response to Enzalutamide or Abiraterone Acetate Post Bipolar Androgen Therapy | 2 Participants |
Secondary
Disease Response as Defined by RECIST 1.1 (Soft Tissue Lesions) and PCWG2 Criteria (Bone Lesions)
Number of participants with complete or partial response post-BAT as defined by RECIST 1.1 (for soft tissue lesions) and PCWG2 criteria (for bone disease), or return to castration-only post-BAT.
Time frame: up to 18 months
Population: 12/30 participants from Cohort A, 7/29 participants from Cohort B, 13/20 from Cohort C, and 7/8 participants from Cohort D were evaluable for this outcome measure.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort A:Post-enzalutamide | Disease Response as Defined by RECIST 1.1 (Soft Tissue Lesions) and PCWG2 Criteria (Bone Lesions) | 6 Participants |
| Cohort B: Post-abiraterone | Disease Response as Defined by RECIST 1.1 (Soft Tissue Lesions) and PCWG2 Criteria (Bone Lesions) | 2 Participants |
| Cohort C: Castration Only | Disease Response as Defined by RECIST 1.1 (Soft Tissue Lesions) and PCWG2 Criteria (Bone Lesions) | 4 Participants |
| Cohort D: Mutation | Disease Response as Defined by RECIST 1.1 (Soft Tissue Lesions) and PCWG2 Criteria (Bone Lesions) | 0 Participants |
Secondary
Initiation of Docetaxel Chemotherapy
Time to initiation of docetaxel chemotherapy
Time frame: up to 18 months
Population: Data was not collected to assess this outcome measure.
Secondary
PSA Progression on BAT (Bipolar Androgen Therapy )
Time to PSA progression on BAT. Time to PSA progression on BAT is defined as the time from the date of initial dose of Testosterone to the date of the PSA measurement when it shows an ≥25% increase above the nadir value and confirmed by a repeat PSA 4 weeks later (PCWG2 criteria) during the treatment with BAT.
Time frame: up to 18 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Cohort A:Post-enzalutamide | PSA Progression on BAT (Bipolar Androgen Therapy ) | 3.3 months |
| Cohort B: Post-abiraterone | PSA Progression on BAT (Bipolar Androgen Therapy ) | 3.2 months |
| Cohort C: Castration Only | PSA Progression on BAT (Bipolar Androgen Therapy ) | 0.93 months |
| Cohort D: Mutation | PSA Progression on BAT (Bipolar Androgen Therapy ) | 3 months |
Secondary
PSA Progression on Enzalutamide or Abiraterone Acetate or Castrate Levels Post-BAT
Time to PSA progression on enzalutamide or abiraterone acetate or return to castrate levels of testosterone post-BAT, defined as the time from the date of re-initiation of enzalutamide or abiraterone acetate or castration-only therapy to the date of the PSA measurement when it shows an increase by ≥25% above the nadir value that occurred following re-initiation of enzalutamide or abiraterone acetate or castration-only therapy and confirmed by a repeat PSA 4 weeks later (PCWG2).
Time frame: up to 18 months
Population: Only 21/30 participants were evaluable from Cohort A. Only 19/29 participants were evaluable from Cohort B.This outcome measure does not apply to Cohort D.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Cohort A:Post-enzalutamide | PSA Progression on Enzalutamide or Abiraterone Acetate or Castrate Levels Post-BAT | 5.5 months |
| Cohort B: Post-abiraterone | PSA Progression on Enzalutamide or Abiraterone Acetate or Castrate Levels Post-BAT | 3.7 months |
| Cohort C: Castration Only | PSA Progression on Enzalutamide or Abiraterone Acetate or Castrate Levels Post-BAT | NA months |
Secondary
Quality of Life (QoL) as Assessed by BPI
Brief Pain Inventory (BPI) assesses the severity of pain and its impact on functioning with scales ranging from 0-10, with a higher score indicating a higher level of pain.
Time frame: up to 18 months
Population: Data was not collected for this outcome measure.
Secondary
Quality of Life (QoL) as Assessed by FACIT-F Score
Functional Assessment of Chronic Illness Therapy, Fatigue Subscale (FACIT-F) assesses Fatigue with a total score range of 0-52, with a higher score reflecting better QoL.
Time frame: up to 18 months
Population: 25/30 participants in Cohort A, 22/29 participants in Cohort B, 28/29 participants in Cohort C were evaluable for this outcome measure. Data was not collected from participants for Cohort D.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Cohort A:Post-enzalutamide | Quality of Life (QoL) as Assessed by FACIT-F Score | Baseline | 13.28 score on a scale | Standard Deviation 6.73 |
| Cohort A:Post-enzalutamide | Quality of Life (QoL) as Assessed by FACIT-F Score | Cycle 1 Day 85 | 10.64 score on a scale | Standard Deviation 5.51 |
| Cohort B: Post-abiraterone | Quality of Life (QoL) as Assessed by FACIT-F Score | Baseline | 16.86 score on a scale | Standard Deviation 7.62 |
| Cohort B: Post-abiraterone | Quality of Life (QoL) as Assessed by FACIT-F Score | Cycle 1 Day 85 | 13.85 score on a scale | Standard Deviation 7.42 |
| Cohort C: Castration Only | Quality of Life (QoL) as Assessed by FACIT-F Score | Baseline | 13 score on a scale | Standard Deviation 5.57 |
| Cohort C: Castration Only | Quality of Life (QoL) as Assessed by FACIT-F Score | Cycle 1 Day 85 | 11.55 score on a scale | Standard Deviation 3.39 |
Secondary
Quality of Life (QoL) as Assessed by IIEF
International Index of Erectile Function (IIEF-5) is a diagnostic tool for erectile dysfunction, with a total score range of 5-25, with the lowest score indicating a higher degree of dysfunction.
Time frame: up to 18 months
Population: 20/30 participants in Cohort A, 21/29 participants in Cohort B, 25/29 participants in Cohort C were evaluable for this outcome measure. Data was not collected from participants in Cohort D.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Cohort A:Post-enzalutamide | Quality of Life (QoL) as Assessed by IIEF | Baseline | 8 score on a scale | Standard Deviation 3.57 |
| Cohort A:Post-enzalutamide | Quality of Life (QoL) as Assessed by IIEF | BAT C1D85 | 24.13 score on a scale | Standard Deviation 21.63 |
| Cohort B: Post-abiraterone | Quality of Life (QoL) as Assessed by IIEF | Baseline | 7.33 score on a scale | Standard Deviation 3.89 |
| Cohort B: Post-abiraterone | Quality of Life (QoL) as Assessed by IIEF | BAT C1D85 | 24.94 score on a scale | Standard Deviation 19.71 |
| Cohort C: Castration Only | Quality of Life (QoL) as Assessed by IIEF | Baseline | 12.56 score on a scale | Standard Deviation 12.86 |
| Cohort C: Castration Only | Quality of Life (QoL) as Assessed by IIEF | BAT C1D85 | 22.44 score on a scale | Standard Deviation 15.53 |
Secondary
Quality of Life (QoL) as Assessed by PANAS
Positive and Negative Affect Schedule (PANAS) is a self-report measure that is made up of two mood scales, one measuring positive affect and the other measuring negative affect, with a total score range from 10-50 with a higher score on the positive scale indicating greater levels of positive affect and a lower score on the negative scale indicating less of a negative affect.
Time frame: up to 18 months
Population: 20/30 participants in Cohort A, 18/29 participants in Cohort B, 25/29 participants in Cohort C were evaluable for this outcome measure. Data was not collected for Cohort D.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Cohort A:Post-enzalutamide | Quality of Life (QoL) as Assessed by PANAS | Baseline | 46.15 score on a scale | Standard Deviation 10.55 |
| Cohort A:Post-enzalutamide | Quality of Life (QoL) as Assessed by PANAS | BAT C1D85 | 45.1 score on a scale | Standard Deviation 9.09 |
| Cohort B: Post-abiraterone | Quality of Life (QoL) as Assessed by PANAS | Baseline | 48 score on a scale | Standard Deviation 11.47 |
| Cohort B: Post-abiraterone | Quality of Life (QoL) as Assessed by PANAS | BAT C1D85 | 45.22 score on a scale | Standard Deviation 12.94 |
| Cohort C: Castration Only | Quality of Life (QoL) as Assessed by PANAS | Baseline | 41.24 score on a scale | Standard Deviation 14.35 |
| Cohort C: Castration Only | Quality of Life (QoL) as Assessed by PANAS | BAT C1D85 | 44.48 score on a scale | Standard Deviation 11.06 |
Secondary
Quality of Life (QoL) as Assessed by RANDSF-36
RAND 36-Item Short Form (RANDSF-36) assesses physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, general health perceptions, and perceived change in health with a total score range of 0-100. The total score from all of the questions answered is divided by the total number of the questions answered yielding a global score from 0-100, with a higher score reflecting a better QoL.
Time frame: up to 18 months
Population: 25/30 participants in Cohort A, 19/29 participants in Cohort B, 25/29 participants in Cohort C were evaluable for this outcome measure. Data was not collected from participants in Cohort D.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Cohort A:Post-enzalutamide | Quality of Life (QoL) as Assessed by RANDSF-36 | Baseline | 72.23 score on a scale | Standard Deviation 18.89 |
| Cohort A:Post-enzalutamide | Quality of Life (QoL) as Assessed by RANDSF-36 | Cycle 1 Day 85 | 71.76 score on a scale | Standard Deviation 19.2 |
| Cohort B: Post-abiraterone | Quality of Life (QoL) as Assessed by RANDSF-36 | Baseline | 64.36 score on a scale | Standard Deviation 18.7 |
| Cohort B: Post-abiraterone | Quality of Life (QoL) as Assessed by RANDSF-36 | Cycle 1 Day 85 | 73.97 score on a scale | Standard Deviation 19.96 |
| Cohort C: Castration Only | Quality of Life (QoL) as Assessed by RANDSF-36 | Baseline | 69.72 score on a scale | Standard Deviation 17.72 |
| Cohort C: Castration Only | Quality of Life (QoL) as Assessed by RANDSF-36 | Cycle 1 Day 85 | 73.40 score on a scale | Standard Deviation 17.98 |
Secondary
Safety and Tolerability as Assessed by Number of Participants With Adverse Events
Number of participants who experience adverse events, as defined by NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.0.
Time frame: 18 months
Population: In cohort D, data was only collected from 7/8 participants.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort A:Post-enzalutamide | Safety and Tolerability as Assessed by Number of Participants With Adverse Events | 30 Participants |
| Cohort B: Post-abiraterone | Safety and Tolerability as Assessed by Number of Participants With Adverse Events | 29 Participants |
| Cohort C: Castration Only | Safety and Tolerability as Assessed by Number of Participants With Adverse Events | 29 Participants |
| Cohort D: Mutation | Safety and Tolerability as Assessed by Number of Participants With Adverse Events | 7 Participants |